FDA Rejection Delays Regeneron From Competing With J&J, Pfizer in Multiple Myeloma

Regeneron Pharmaceuticals said the FDA cited no approvability concerns for its multiple myeloma drug, linvoseltamab, other than previously identified issues with a contract manufacturer. While linvoseltamab trails bispecific antibodies currently marketed by Johnson & Johnson and Pfizer, if approved, it could bring patients an earlier treatment option. The post FDA Rejection Delays Regeneron From Competing…

Read More

Journalists Weigh In on Racial Trauma, Medicaid Expansion, and Opioid Settlements

KFF Health News Midwest correspondent Cara Anthony discussed healing from racial trauma on “America’s Heroes Group” on Sept. 20. Click here to watch Anthony on “America’s Heroes Group” Explore Anthony’s series on the topic, “Silence in Sikeston” KFF Health News contributor Andy Miller discussed Medicaid expansion in Georgia on WUGA’s “The Georgia Health Report” on Sept….

Read More

Trump Team Takes Aim at State Laws Shielding Consumers’ Credit Scores From Medical Debt

The Trump administration took another step Tuesday to weaken protections for Americans with medical debt, issuing new guidance that threatens ongoing state efforts to keep that debt off consumers’ credit reports. More than a dozen states, including Washington, Oregon, California, Colorado, Minnesota, Maryland, New York, and most of New England, have enacted laws in recent…

Read More

Mientras científicos estudian la propagación del sarampión en el país, Kennedy pone en riesgo avances que costaron décadas

Estados Unidos está a punto de perder su estatus de país libre de sarampión el próximo año. Si eso sucede, entraría en una nueva etapa en la que los brotes volverían a ser comunes. Más niñas y niños serían hospitalizados por esta enfermedad prevenible. Algunos perderían la audición. Algunos morirían. El sarampión también es costoso….

Read More

Denial prevention: Why manage denials when you can prevent them?

The denial challenge is getting tougher. In Experian Health’s latest State of Claims 2024 survey, almost three-quarters of healthcare administrators agree that claim denials are increasing. The majority also agree that difficulties with claims—like reimbursement times, errors, and payer policy changes—are becoming more common. It’s no surprise that denial prevention is a priority for 84% of respondents….

Read More